Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 704

1.

Icosapent Ethyl Reduces Atherogenic Markers in High-Risk Statin-Treated Patients With Stage 3 Chronic Kidney Disease and High Triglycerides.

Vijayaraghavan K, Szerlip HM, Ballantyne CM, Bays HE, Philip S, Doyle RT, Juliano RA, Granowitz C.

Postgrad Med. 2019 Jul 15. doi: 10.1080/00325481.2019.1643633. [Epub ahead of print]

PMID:
31306043
2.

Seven Metrics That Will Determine Your Cardiovascular Success or Failure.

Ballantyne CM, Nambi V.

JACC Heart Fail. 2019 Jul 3. pii: S2213-1779(19)30265-3. doi: 10.1016/j.jchf.2019.04.008. [Epub ahead of print] No abstract available.

PMID:
31302041
3.

Effects of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Atherogenic Lipid/Lipoprotein, Apolipoprotein, and Inflammatory Parameters in Patients With Elevated High-Sensitivity C-Reactive Protein (from the ANCHOR Study).

Miller M, Ballantyne CM, Bays HE, Granowitz C, Doyle RT Jr, Juliano RA, Philip S.

Am J Cardiol. 2019 Jun 6. pii: S0002-9149(19)30637-X. doi: 10.1016/j.amjcard.2019.05.057. [Epub ahead of print]

4.

Lipoprotein(a) and Risk for Stroke and Myocardial Infarction: Why Aren't We Screening?

Ballantyne CM.

J Am Coll Cardiol. 2019 Jul 9;74(1):67-69. doi: 10.1016/j.jacc.2019.05.029. No abstract available.

PMID:
31272553
5.

Statin use in carnitine palmitoyltransferase II deficiency.

Saeed A, Hadley TD, Jia X, Ballantyne CM.

J Clin Lipidol. 2019 May 10. pii: S1933-2874(19)30176-X. doi: 10.1016/j.jacl.2019.05.001. [Epub ahead of print] No abstract available.

PMID:
31235404
6.

Use of Guideline-Recommended Risk-Reduction Strategies Among Patients with Diabetes and Atherosclerotic Cardiovascular Disease: Insights from Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD).

Arnold SV, de Lemos JA, Rosenson RS, Ballantyne CM, Liu Y, Mues KE, Alam S, Elliott-Davey M, Bhatt DL, Cannon CP, Kosiborod M; GOULD Investigators.

Circulation. 2019 Jun 7. doi: 10.1161/CIRCULATIONAHA.119.041730. [Epub ahead of print]

PMID:
31174429
7.

Association Between Lipid Testing and Statin Adherence in the Veterans Affairs Health System.

Jia X, Al Rifai M, Ramsey DJ, Ahmed ST, Akeroyd JM, Nambi V, Ballantyne CM, Petersen LA, Stone NJ, Virani SS.

Am J Med. 2019 May 17. pii: S0002-9343(19)30332-8. doi: 10.1016/j.amjmed.2019.04.002. [Epub ahead of print]

PMID:
31103643
8.

Metabolomic Pattern Predicts Incident Coronary Heart Disease.

Wang Z, Zhu C, Nambi V, Morrison AC, Folsom AR, Ballantyne CM, Boerwinkle E, Yu B.

Arterioscler Thromb Vasc Biol. 2019 Jul;39(7):1475-1482. doi: 10.1161/ATVBAHA.118.312236. Epub 2019 May 16.

PMID:
31092011
9.

Relation of Isolated Systolic Hypertension and Pulse Pressure to High-Sensitivity Cardiac Troponin-T and N-Terminal pro-B-Type Natriuretic Peptide in Older Adults (from the Atherosclerosis Risk in Communities Study).

Madan N, Lee AK, Matsushita K, Hoogeveen RC, Ballantyne CM, Selvin E, McEvoy JW.

Am J Cardiol. 2019 Jul 15;124(2):245-252. doi: 10.1016/j.amjcard.2019.04.030. Epub 2019 Apr 23.

PMID:
31088661
10.

High-sensitivity Cardiac Troponin and Natriuretic Peptide in Persons Without Cardiovascular Disease and Subsequent Risk of Infection: Atherosclerosis Risk in Communities Study.

Ishigami J, Hoogeveen RC, Ballantyne CM, Folsom AR, Coresh J, Selvin E, Matsushita K.

Am J Epidemiol. 2019 May 7. pii: kwz113. doi: 10.1093/aje/kwz113. [Epub ahead of print]

PMID:
31063194
11.

Poststatin Lipid Therapeutics: A Review.

Jia X, Lorenz P, Ballantyne CM.

Methodist Debakey Cardiovasc J. 2019 Jan-Mar;15(1):32-38. doi: 10.14797/mdcj-15-1-32. Review.

12.

ApoB, small-dense LDL-C, Lp(a), LpPLA2 activity, and cognitive change.

Pokharel Y, Mouhanna F, Nambi V, Virani SS, Hoogeveen R, Alonso A, Heiss G, Coresh J, Mosley T, Gottesman RF, Ballantyne CM, Power MC.

Neurology. 2019 May 28;92(22):e2580-e2593. doi: 10.1212/WNL.0000000000007574. Epub 2019 May 1.

PMID:
31043469
13.

High-Sensitivity Troponin I and Incident Coronary Events, Stroke, Heart Failure Hospitalization, and Mortality in the ARIC Study.

Jia X, Sun W, Hoogeveen RC, Nambi V, Matsushita K, Folsom AR, Heiss G, Couper DJ, Solomon SD, Boerwinkle E, Shah A, Selvin E, de Lemos JA, Ballantyne CM.

Circulation. 2019 Jun 4;139(23):2642-2653. doi: 10.1161/CIRCULATIONAHA.118.038772. Epub 2019 Apr 29.

PMID:
31030544
14.
15.

Facility-Level Variation in Stress Test Utilization in Veterans With Ischemic Heart Disease.

Shah NR, Ahmed ST, Winchester DE, Ramsey DJ, Akeroyd JM, Wu WC, Waldo SW, Schofield RS, Ballantyne CM, Petersen LA, Virani SS.

JACC Cardiovasc Imaging. 2019 Jul;12(7 Pt 1):1292-1293. doi: 10.1016/j.jcmg.2019.02.020. Epub 2019 Apr 17. No abstract available.

PMID:
31005521
16.

Cancer Survivorship and Subclinical Myocardial Damage: The Atherosclerosis Risk in Communities (ARIC) Study.

Florido R, Lee AK, McEvoy JW, Hoogeveen RC, Koton S, Vitolins MZ, Shenoy C, Russell SD, Blumenthal RS, Ndumele CE, Ballantyne CM, Joshu CE, Platz EA, Selvin E.

Am J Epidemiol. 2019 Mar 30. pii: kwz088. doi: 10.1093/aje/kwz088. [Epub ahead of print]

PMID:
30927355
17.

Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT.

Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Gregson J, Pocock SJ, Ballantyne CM; REDUCE-IT Investigators.

J Am Coll Cardiol. 2019 Jun 11;73(22):2791-2802. doi: 10.1016/j.jacc.2019.02.032. Epub 2019 Mar 18.

18.

Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events.

Patel RS, Schmidt AF, Tragante V, McCubrey RO, Holmes MV, Howe LJ, Direk K, Åkerblom A, Leander K, Virani SS, Kaminski KA, Muehlschlegel JD, Dubé MP, Allayee H, Almgren P, Alver M, Baranova EV, Behlouli H, Boeckx B, Braund PS, Breitling LP, Delgado G, Duarte NE, Dufresne L, Eriksson N, Foco L, Gijsberts CM, Gong Y, Hartiala J, Heydarpour M, Hubacek JA, Kleber M, Kofink D, Kuukasjärvi P, Lee VV, Leiherer A, Lenzini PA, Levin D, Lyytikäinen LP, Martinelli N, Mons U, Nelson CP, Nikus K, Pilbrow AP, Ploski R, Sun YV, Tanck MWT, Tang WHW, Trompet S, van der Laan SW, van Setten J, Vilmundarson RO, Viviani Anselmi C, Vlachopoulou E, Boerwinkle E, Briguori C, Carlquist JF, Carruthers KF, Casu G, Deanfield J, Deloukas P, Dudbridge F, Fitzpatrick N, Gigante B, James S, Lokki ML, Lotufo PA, Marziliano N, Mordi IR, Muhlestein JB, Newton Cheh C, Pitha J, Saely CH, Samman-Tahhan A, Sandesara PB, Teren A, Timmis A, Van de Werf F, Wauters E, Wilde AAM, Ford I, Stott DJ, Algra A, Andreassi MG, Ardissino D, Arsenault BJ, Ballantyne CM, Bergmeijer TO, Bezzina CR, Body SC, Bogaty P, de Borst GJ, Brenner H, Burkhardt R, Carpeggiani C, Condorelli G, Cooper-DeHoff RM, Cresci S, de Faire U, Doughty RN, Drexel H, Engert JC, Fox KAA, Girelli D, Hagström E, Hazen SL, Held C, Hemingway H, Hoefer IE, Hovingh GK, Johnson JA, de Jong PA, Jukema JW, Kaczor MP, Kähönen M, Kettner J, Kiliszek M, Klungel OH, Lagerqvist B, Lambrechts D, Laurikka JO, Lehtimäki T, Lindholm D, Mahmoodi BK, Maitland-van der Zee AH, McPherson R, Melander O, Metspalu A, Pepinski W, Olivieri O, Opolski G, Palmer CN, Pasterkamp G, Pepine CJ, Pereira AC, Pilote L, Quyyumi AA, Richards AM, Sanak M, Scholz M, Siegbahn A, Sinisalo J, Smith JG, Spertus JA, Stewart AFR, Szczeklik W, Szpakowicz A, Ten Berg JM, Thanassoulis G, Thiery J, van der Graaf Y, Visseren FLJ, Waltenberger J; CARDIoGRAMPlusC4D Consortium, Van der Harst P, Tardif JC, Sattar N, Lang CC, Pare G, Brophy JM, Anderson JL, März W, Wallentin L, Cameron VA, Horne BD, Samani NJ, Hingorani AD, Asselbergs FW.

Circ Genom Precis Med. 2019 Apr;12(4):e002471. doi: 10.1161/CIRCGEN.119.002471. Epub 2019 Mar 21.

PMID:
30897348
19.

Subsequent Event Risk in Individuals With Established Coronary Heart Disease.

Patel RS, Tragante V, Schmidt AF, McCubrey RO, Holmes MV, Howe LJ, Direk K, Åkerblom A, Leander K, Virani SS, Kaminski KA, Muehlschlegel JD, Allayee H, Almgren P, Alver M, Baranova EV, Behloui H, Boeckx B, Braund PS, Breitling LP, Delgado G, Duarte NE, Dubé MP, Dufresne L, Eriksson N, Foco L, Scholz M, Gijsberts CM, Glinge C, Gong Y, Hartiala J, Heydarpour M, Hubacek JA, Kleber M, Kofink D, Kotti S, Kuukasjärvi P, Lee VV, Leiherer A, Lenzini PA, Levin D, Lyytikäinen LP, Martinelli N, Mons U, Nelson CP, Nikus K, Pilbrow AP, Ploski R, Sun YV, Tanck MWT, Tang WHW, Trompet S, van der Laan SW, Van Setten J, Vilmundarson RO, Viviani Anselmi C, Vlachopoulou E, Al Ali L, Boerwinkle E, Briguori C, Carlquist JF, Carruthers KF, Casu G, Deanfield J, Deloukas P, Dudbridge F, Engstrøm T, Fitzpatrick N, Fox K, Gigante B, James S, Lokki ML, Lotufo PA, Marziliano N, Mordi IR, Muhlestein JB, Newton-Cheh C, Pitha J, Saely CH, Samman-Tahhan A, Sandesara PB, Teren A, Timmis A, Van de Werf F, Wauters E, Wilde AAM, Ford I, Stott DJ, Algra A, Andreassi MG, Ardissino D, Arsenault BJ, Ballantyne CM, Bergmeijer TO, Bezzina CR, Body SC, Boersma EH, Bogaty P, Bots ML, Brenner H, Brugts JJ, Burkhardt R, Carpeggiani C, Condorelli G, Cooper-DeHoff RM, Cresci S, Danchin N, de Faire U, Doughty RN, Drexel H, Engert JC, Fox KAA, Girelli D, Grobbee DE, Hagström E, Hazen SL, Held C, Hemingway H, Hoefer IE, Hovingh GK, Jabbari R, Johnson JA, Jukema JW, Kaczor MP, Kähönen M, Kettner J, Kiliszek M, Klungel OH, Lagerqvist B, Lambrechts D, Laurikka JO, Lehtimäki T, Lindholm D, Mahmoodi BK, Maitland-van der Zee AH, McPherson R, Melander O, Metspalu A, Niemcunowicz-Janica A, Olivieri O, Opolski G, Palmer CN, Pasterkamp G, Pepine CJ, Pereira AC, Pilote L, Quyyumi AA, Richards AM, Sanak M, Siegbahn A, Simon T, Sinisalo J, Smith JG, Spertus JA, Stender S, Stewart AFR, Szczeklik W, Szpakowicz A, Tardif JC, Ten Berg JM, Tfelt-Hansen J, Thanassoulis G, Thiery J, Torp-Pedersen C, van der Graaf Y, Visseren FLJ, Waltenberger J, Weeke PE, Van der Harst P, Lang CC, Sattar N, Cameron VA, Anderson JL, Brophy JM, Pare G, Horne BD, März W, Wallentin L, Samani NJ, Hingorani AD, Asselbergs FW.

Circ Genom Precis Med. 2019 Apr;12(4):e002470. doi: 10.1161/CIRCGEN.119.002470. Epub 2019 Mar 21.

PMID:
30896328
20.

Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol.

Ray KK, Bays HE, Catapano AL, Lalwani ND, Bloedon LT, Sterling LR, Robinson PL, Ballantyne CM; CLEAR Harmony Trial.

N Engl J Med. 2019 Mar 14;380(11):1022-1032. doi: 10.1056/NEJMoa1803917.

PMID:
30865796
21.

Eligibility and Cost for Icosapent Ethyl Based on the REDUCE-IT Trial.

Jia X, Akeroyd JM, Nasir K, Nambi V, Ballantyne CM, Petersen LA, Virani SS.

Circulation. 2019 Mar 5;139(10):1341-1343. doi: 10.1161/CIRCULATIONAHA.118.038691. No abstract available.

PMID:
30865483
22.

Central and peripheral pulse wave velocity and subclinical myocardial stress and damage in older adults.

Liu S, Kim ED, Wu A, Meyer ML, Cheng S, Hoogeveen RC, Ballantyne CM, Tanaka H, Heiss G, Selvin E, Matsushita K.

PLoS One. 2019 Feb 27;14(2):e0212892. doi: 10.1371/journal.pone.0212892. eCollection 2019.

23.

Icosapent Ethyl Effects on Fatty Acid Profiles in Statin-Treated Patients With High Triglycerides: The Randomized, Placebo-controlled ANCHOR Study.

Ballantyne CM, Manku MS, Bays HE, Philip S, Granowitz C, Doyle RT Jr, Juliano RA.

Cardiol Ther. 2019 Jun;8(1):79-90. doi: 10.1007/s40119-019-0131-8. Epub 2019 Feb 20.

24.

Sleep apnea and galectin-3: possible sex-specific relationship.

Singh M, Hanis CL, Redline S, Ballantyne CM, Hamzeh I, Aguilar D.

Sleep Breath. 2019 Feb 5. doi: 10.1007/s11325-019-01788-5. [Epub ahead of print]

PMID:
30721387
25.

Lipoprotein(a) levels and risk of cardiovascular disease events in individuals with diabetes mellitus or prediabetes: The Atherosclerosis Risk in Communities study.

Saeed A, Sun W, Agarwala A, Virani SS, Nambi V, Coresh J, Selvin E, Boerwinkle E, Jones PH, Ballantyne CM, Hoogeveen RC.

Atherosclerosis. 2019 Mar;282:52-56. doi: 10.1016/j.atherosclerosis.2018.12.022. Epub 2018 Dec 30.

PMID:
30685442
26.

Association of Body Mass Index With Risk Factor Optimization and Guideline-Directed Medical Therapy in US Veterans With Cardiovascular Disease.

Hira RS, Kataruka A, Akeroyd JM, Ramsey DJ, Pokharel Y, Gurm HS, Nasir K, Deswal A, Jneid H, Alam M, Ballantyne CM, Petersen LA, Virani SS.

Circ Cardiovasc Qual Outcomes. 2019 Jan;12(1):e004817. doi: 10.1161/CIRCOUTCOMES.118.004817.

PMID:
30636483
27.

Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial.

Virani SS, Akeroyd JM, Nambi V, Michos ED, Morris PB, Nasir K, Smith SC Jr, Stone NJ, Petersen LA, Ballantyne CM.

Circulation. 2019 Jan 15;139(3):410-412. doi: 10.1161/CIRCULATIONAHA.118.034993. No abstract available.

PMID:
30586689
28.

Low-Density Lipoprotein Cholesterol: Is 160 the New 190?

Virani SS, Ballantyne CM.

Circulation. 2018 Nov 20;138(21):2326-2329. doi: 10.1161/CIRCULATIONAHA.118.034922. No abstract available.

PMID:
30571588
29.

Association of Cardiac Injury and Malignant Left Ventricular Hypertrophy With Risk of Heart Failure in African Americans: The Jackson Heart Study.

Pandey A, Keshvani N, Ayers C, Correa A, Drazner MH, Lewis A, Rodriguez CJ, Hall ME, Fox ER, Mentz RJ, deFilippi C, Seliger SL, Ballantyne CM, Neeland IJ, de Lemos JA, Berry JD.

JAMA Cardiol. 2019 Jan 1;4(1):51-58. doi: 10.1001/jamacardio.2018.4300.

PMID:
30566191
30.

Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia.

Reeskamp LF, Kastelein JJP, Moriarty PM, Duell PB, Catapano AL, Santos RD, Ballantyne CM.

Atherosclerosis. 2019 Jan;280:109-117. doi: 10.1016/j.atherosclerosis.2018.11.017. Epub 2018 Nov 10.

PMID:
30500603
31.

Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.

Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM; REDUCE-IT Investigators.

N Engl J Med. 2019 Jan 3;380(1):11-22. doi: 10.1056/NEJMoa1812792. Epub 2018 Nov 10.

PMID:
30415628
32.

Genome Analyses of >200,000 Individuals Identify 58 Loci for Chronic Inflammation and Highlight Pathways that Link Inflammation and Complex Disorders.

Ligthart S, Vaez A, Võsa U, Stathopoulou MG, de Vries PS, Prins BP, Van der Most PJ, Tanaka T, Naderi E, Rose LM, Wu Y, Karlsson R, Barbalic M, Lin H, Pool R, Zhu G, Macé A, Sidore C, Trompet S, Mangino M, Sabater-Lleal M, Kemp JP, Abbasi A, Kacprowski T, Verweij N, Smith AV, Huang T, Marzi C, Feitosa MF, Lohman KK, Kleber ME, Milaneschi Y, Mueller C, Huq M, Vlachopoulou E, Lyytikäinen LP, Oldmeadow C, Deelen J, Perola M, Zhao JH, Feenstra B; LifeLines Cohort Study, Amini M; CHARGE Inflammation Working Group, Lahti J, Schraut KE, Fornage M, Suktitipat B, Chen WM, Li X, Nutile T, Malerba G, Luan J, Bak T, Schork N, Del Greco M F, Thiering E, Mahajan A, Marioni RE, Mihailov E, Eriksson J, Ozel AB, Zhang W, Nethander M, Cheng YC, Aslibekyan S, Ang W, Gandin I, Yengo L, Portas L, Kooperberg C, Hofer E, Rajan KB, Schurmann C, den Hollander W, Ahluwalia TS, Zhao J, Draisma HHM, Ford I, Timpson N, Teumer A, Huang H, Wahl S, Liu Y, Huang J, Uh HW, Geller F, Joshi PK, Yanek LR, Trabetti E, Lehne B, Vozzi D, Verbanck M, Biino G, Saba Y, Meulenbelt I, O'Connell JR, Laakso M, Giulianini F, Magnusson PKE, Ballantyne CM, Hottenga JJ, Montgomery GW, Rivadineira F, Rueedi R, Steri M, Herzig KH, Stott DJ, Menni C, Frånberg M, St Pourcain B, Felix SB, Pers TH, Bakker SJL, Kraft P, Peters A, Vaidya D, Delgado G, Smit JH, Großmann V, Sinisalo J, Seppälä I, Williams SR, Holliday EG, Moed M, Langenberg C, Räikkönen K, Ding J, Campbell H, Sale MM, Chen YI, James AL, Ruggiero D, Soranzo N, Hartman CA, Smith EN, Berenson GS, Fuchsberger C, Hernandez D, Tiesler CMT, Giedraitis V, Liewald D, Fischer K, Mellström D, Larsson A, Wang Y, Scott WR, Lorentzon M, Beilby J, Ryan KA, Pennell CE, Vuckovic D, Balkau B, Concas MP, Schmidt R, Mendes de Leon CF, Bottinger EP, Kloppenburg M, Paternoster L, Boehnke M, Musk AW, Willemsen G, Evans DM, Madden PAF, Kähönen M, Kutalik Z, Zoledziewska M, Karhunen V, Kritchevsky SB, Sattar N, Lachance G, Clarke R, Harris TB, Raitakari OT, Attia JR, van Heemst D, Kajantie E, Sorice R, Gambaro G, Scott RA, Hicks AA, Ferrucci L, Standl M, Lindgren CM, Starr JM, Karlsson M, Lind L, Li JZ, Chambers JC, Mori TA, de Geus EJCN, Heath AC, Martin NG, Auvinen J, Buckley BM, de Craen AJM, Waldenberger M, Strauch K, Meitinger T, Scott RJ, McEvoy M, Beekman M, Bombieri C, Ridker PM, Mohlke KL, Pedersen NL, Morrison AC, Boomsma DI, Whitfield JB, Strachan DP, Hofman A, Vollenweider P, Cucca F, Jarvelin MR, Jukema JW, Spector TD, Hamsten A, Zeller T, Uitterlinden AG, Nauck M, Gudnason V, Qi L, Grallert H, Borecki IB, Rotter JI, März W, Wild PS, Lokki ML, Boyle M, Salomaa V, Melbye M, Eriksson JG, Wilson JF, Penninx BWJH, Becker DM, Worrall BB, Gibson G, Krauss RM, Ciullo M, Zaza G, Wareham NJ, Oldehinkel AJ, Palmer LJ, Murray SS, Pramstaller PP, Bandinelli S, Heinrich J, Ingelsson E, Deary IJ, Mägi R, Vandenput L, van der Harst P, Desch KC, Kooner JS, Ohlsson C, Hayward C, Lehtimäki T, Shuldiner AR, Arnett DK, Beilin LJ, Robino A, Froguel P, Pirastu M, Jess T, Koenig W, Loos RJF, Evans DA, Schmidt H, Smith GD, Slagboom PE, Eiriksdottir G, Morris AP, Psaty BM, Tracy RP, Nolte IM, Boerwinkle E, Visvikis-Siest S, Reiner AP, Gross M, Bis JC, Franke L, Franco OH, Benjamin EJ, Chasman DI, Dupuis J, Snieder H, Dehghan A, Alizadeh BZ.

Am J Hum Genet. 2018 Nov 1;103(5):691-706. doi: 10.1016/j.ajhg.2018.09.009.

33.

Effect of Evolocumab on Coronary Plaque Composition.

Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJP, Koenig W, Somaratne R, Kassahun H, Yang J, Wasserman SM, Honda S, Shishikura D, Scherer DJ, Borgman M, Brennan DM, Wolski K, Nissen SE.

J Am Coll Cardiol. 2018 Oct 23;72(17):2012-2021. doi: 10.1016/j.jacc.2018.06.078.

PMID:
30336824
34.

Case reports of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition nonresponse.

Saeed A, Virani SS, Jones PH, Ballantyne CM, Nambi V.

J Clin Lipidol. 2018 Sep - Oct;12(5):1141-1145. doi: 10.1016/j.jacl.2018.05.017. Epub 2018 Jun 1.

PMID:
30318064
35.

WITHDRAWN: Raising the Bar by Lowering the Target: Integrating PCSK9 Inhibitors Into Hypercholesterolemia Management.

Ballantyne CM, Bhatt DL, Cannon CP, Fazio S, Sabatine MS.

Am J Cardiol. 2018 Aug 16. pii: S0002-9149(18)31653-9. doi: 10.1016/j.amjcard.2018.08.020. [Epub ahead of print] No abstract available.

PMID:
30301542
36.

Prospective Study of Endogenous Hormones and Incidence of Venous Thromboembolism: The Atherosclerosis Risk in Communities Study.

Roetker NS, MacLehose RF, Hoogeveen RC, Ballantyne CM, Basu S, Cushman M, Folsom AR.

Thromb Haemost. 2018 Nov;118(11):1940-1950. doi: 10.1055/s-0038-1673613. Epub 2018 Oct 8.

PMID:
30296818
37.

Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial.

Nicholls SJ, Lincoff AM, Bash D, Ballantyne CM, Barter PJ, Davidson MH, Kastelein JJP, Koenig W, McGuire DK, Mozaffarian D, Pedersen TR, Ridker PM, Ray K, Karlson BW, Lundström T, Wolski K, Nissen SE.

Clin Cardiol. 2018 Oct;41(10):1281-1288. doi: 10.1002/clc.23055. Epub 2018 Sep 28. Review.

38.

Are All Benefits and Harms Equal?

Saeed A, Virani SS, Ballantyne CM, Taylor AA, Nambi V.

J Am Coll Cardiol. 2018 Aug 14;72(7):819-820. doi: 10.1016/j.jacc.2018.05.055. No abstract available.

PMID:
30092962
39.

Diagnostic Performance of 1,5-Anhydroglucitol Compared to 2-H Glucose in the Atherosclerosis Risk in Communities Study.

Warren B, Lee AK, Ballantyne CM, Hoogeveen RC, Pankow JS, Grams M, Köttgen A, Selvin E.

Clin Chem. 2018 Oct;64(10):1536-1537. doi: 10.1373/clinchem.2018.291773. Epub 2018 Aug 7. No abstract available.

PMID:
30087139
40.

Clinical Genetic Testing for Familial Hypercholesterolemia: JACC Scientific Expert Panel.

Sturm AC, Knowles JW, Gidding SS, Ahmad ZS, Ahmed CD, Ballantyne CM, Baum SJ, Bourbon M, Carrié A, Cuchel M, de Ferranti SD, Defesche JC, Freiberger T, Hershberger RE, Hovingh GK, Karayan L, Kastelein JJP, Kindt I, Lane SR, Leigh SE, Linton MF, Mata P, Neal WA, Nordestgaard BG, Santos RD, Harada-Shiba M, Sijbrands EJ, Stitziel NO, Yamashita S, Wilemon KA, Ledbetter DH, Rader DJ; Convened by the Familial Hypercholesterolemia Foundation.

J Am Coll Cardiol. 2018 Aug 7;72(6):662-680. doi: 10.1016/j.jacc.2018.05.044. Review.

PMID:
30071997
41.

Effect of Infusion of High-Density Lipoprotein Mimetic Containing Recombinant Apolipoprotein A-I Milano on Coronary Disease in Patients With an Acute Coronary Syndrome in the MILANO-PILOT Trial: A Randomized Clinical Trial.

Nicholls SJ, Puri R, Ballantyne CM, Jukema JW, Kastelein JJP, Koenig W, Wright RS, Kallend D, Wijngaard P, Borgman M, Wolski K, Nissen SE.

JAMA Cardiol. 2018 Sep 1;3(9):806-814. doi: 10.1001/jamacardio.2018.2112.

PMID:
30046837
42.

Longitudinal increases in blood biomarkers of inflammation or cardiovascular disease and the incidence of venous thromboembolism.

Folsom AR, Lutsey PL, Heckbert SR, Poudel K, Basu S, Hoogeveen RC, Cushman M, Ballantyne CM.

J Thromb Haemost. 2018 Oct;16(10):1964-1972. doi: 10.1111/jth.14241. Epub 2018 Aug 11.

PMID:
30007116
43.

Remnant-Like Particle Cholesterol, Low-Density Lipoprotein Triglycerides, and Incident Cardiovascular Disease.

Saeed A, Feofanova EV, Yu B, Sun W, Virani SS, Nambi V, Coresh J, Guild CS, Boerwinkle E, Ballantyne CM, Hoogeveen RC.

J Am Coll Cardiol. 2018 Jul 10;72(2):156-169. doi: 10.1016/j.jacc.2018.04.050.

44.

Effectiveness of NPs and PAs in managing diabetes and cardiovascular disease.

Faza NN, Akeroyd JM, Ramsey DJ, Shah T, Nasir K, Deswal A, Ballantyne CM, Petersen LA, Virani SS.

JAAPA. 2018 Jul;31(7):39-45. doi: 10.1097/01.JAA.0000534983.61613.91. Erratum in: JAAPA. 2019 Jun;32(6):1.

PMID:
29957606
45.

Correction to: Cardiovascular Disease Prevention: Training Opportunities, the Challenges, and Future Directions.

Saeed A, Dabhadkar K, Virani SS, Jones PH, Ballantyne CM, Nambi V.

Curr Atheroscler Rep. 2018 Jun 19;20(9):42. doi: 10.1007/s11883-018-0743-9.

PMID:
29915890
46.

Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study.

Ballantyne CM, Banach M, Mancini GBJ, Lepor NE, Hanselman JC, Zhao X, Leiter LA.

Atherosclerosis. 2018 Oct;277:195-203. doi: 10.1016/j.atherosclerosis.2018.06.002. Epub 2018 Jun 12.

47.

Critical role of integrin CD11c in splenic dendritic cell capture of missing-self CD47 cells to induce adaptive immunity.

Wu J, Wu H, An J, Ballantyne CM, Cyster JG.

Proc Natl Acad Sci U S A. 2018 Jun 26;115(26):6786-6791. doi: 10.1073/pnas.1805542115. Epub 2018 Jun 11.

48.

Ticagrelor Use in Acute Myocardial Infarction: Insights From the National Cardiovascular Data Registry.

Basra SS, Wang TY, Simon DN, Chiswell K, Virani SS, Alam M, Nambi V, Denktas AE, Deswal A, Bozkurt B, Ballantyne CM, Peterson ED, Jneid H.

J Am Heart Assoc. 2018 Jun 9;7(12). pii: e008125. doi: 10.1161/JAHA.117.008125.

49.

Plasma Galectin-3 and Sonographic Measures of Carotid Atherosclerosis in the Atherosclerosis Risk in Communities Study.

Oyenuga A, Folsom AR, Fashanu O, Aguilar D, Ballantyne CM.

Angiology. 2019 Jan;70(1):47-55. doi: 10.1177/0003319718780772. Epub 2018 Jun 7.

PMID:
29879846
50.

Discovery, fine-mapping, and conditional analyses of genetic variants associated with C-reactive protein in multiethnic populations using the Metabochip in the Population Architecture using Genomics and Epidemiology (PAGE) study.

Kocarnik JM, Richard M, Graff M, Haessler J, Bien S, Carlson C, Carty CL, Reiner AP, Avery CL, Ballantyne CM, LaCroix AZ, Assimes TL, Barbalic M, Pankratz N, Tang W, Tao R, Chen D, Talavera GA, Daviglus ML, Chirinos-Medina DA, Pereira R, Nishimura K, Bužková P, Best LG, Ambite JL, Cheng I, Crawford DC, Hindorff LA, Fornage M, Heiss G, North KE, Haiman CA, Peters U, Le Marchand L, Kooperberg C.

Hum Mol Genet. 2018 Aug 15;27(16):2940-2953. doi: 10.1093/hmg/ddy211.

PMID:
29878111

Supplemental Content

Loading ...
Support Center